Agios Pharmaceuticals, Inc. (AGIO)
| Market Cap | 1.59B |
| Revenue (ttm) | 44.79M |
| Net Income (ttm) | -401.27M |
| Shares Out | 58.31M |
| EPS (ttm) | -6.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 982,193 |
| Open | 27.02 |
| Previous Close | 27.16 |
| Day's Range | 26.66 - 27.41 |
| 52-Week Range | 22.24 - 46.00 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 35.63 (+30.37%) |
| Earnings Date | Feb 12, 2026 |
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patien... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price target is $35.63, which is an increase of 30.37% from the latest price.
News
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
Agios Pharma Stock: A Buy After FDA Approves Aqvesme
Agios Pharmaceuticals upgraded to buy (market perform) after FDA approval of Aqvesme for Alpha- or Beta-Thalassemia, despite boxed warning for liver injury. AGIO's commercial upside from thalassemia i...
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat
Shares of Agios Pharmaceuticals surged nearly 15% in premarket trading on Wednesday after the US Food and Drug Administration approved an expanded use of its drug mitapivat, strengthening investor opt...
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
Shares of Agios Pharmaceuticals jumped nearly 12% premarket on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder...
U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemi...
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
Agios today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the sNDA for mitapivat in thalassemia
Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript
Agios Pharmaceuticals, Inc. ( AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease November 19, 2025 8:00 AM EST Company Participants Morgan Sanford Brian Go...
Why Is Agios Pharmaceuticals Stock Sinking Today?
Agios Pharmaceuticals Inc. (NASDAQ: AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.
Agios Pharma reports mixed results in late-stage study for sickle cell disease drug
Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction...
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did n...
Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones
Agios Pharmaceuticals delivered strong Q3'25 results, with revenue up 44% year-over-year and continued momentum in its rare-disease pipeline. AGIO's key catalysts include the FDA decision on Pyrukynd'...
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit...
Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript
Agios Pharmaceuticals, Inc. ( AGIO) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Morgan Sanford Brian Goff - CEO & Director Cecilia Jones - Chief Financial Officer Tsveta M...
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
$12.9 million in third quarter PYRUKYND® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassem...
Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia
AMSTERDAM--(BUSINESS WIRE)-- #biopharma--Avanzanite's Partner Agios Pharmaceuticals Announces Regulatory Update.
Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
Agios today announced that the CHMP has adopted a positive opinion for the new indication for PYRUKYND in adults for anemia associated with thalassemia
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
Agios today announced the company will host a conference call and live webcast on Thursday, October 30, 2025, at 8:00 a.m. ET to report its third quarter
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , Sept. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agios Pharmaceutica...
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $AGIO--AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.
Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive
Agios faces a pivotal FDA decision on 7 December for mitapivat's thalassemia expansion, with a good chance of approval based on strong Phase 3 data. The stock has lagged typical pre-PDUFA momentum, of...
Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated
Agios Pharmaceuticals, Inc. faces a three-month FDA review delay for mitapivat in thalassemia due to safety concerns, but no new efficacy or safety data was requested. Despite the setback, I remain co...
FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use
On Thursday, the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for Agios Pharmaceuticals, Inc.'s AGIO supplemental New Drug Application (sNDA) o...
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage...
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia
Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Brian M. Goff - CEO & Director Cecilia Jones - Chief Financial Officer Sarah Gheuens - Ch...